Pharmaceutical Technology

FEBRUARY 16, 2023

The collaboration will combine the Optejet dispensing technology of Eyenovia with the APNT nanoparticle formulation platform of Formosa to develop topical therapeutics. Under the deal, both companies will work together to develop new drugs using APNT formulations in the Optejet dispenser.

Drug Delivery 147

Drug Delivery Compliance Development Drugs 147

Pharmaceutical Technology

FEBRUARY 8, 2023

Under the deal, AGC Biologics will be responsible for manufacturing the cell therapy lentivirus-based product for the ongoing clinical programmes of Genenta Science. Genenta stated that the services offered under the existing deal are in addition to those offered under the agreement signed with AGC Biologics.

Manufacturing 130

Manufacturing Gene Therapy Production Clinical Trials 130

Pharmaceutical Technology

JULY 5, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of TeneoTwo as well as its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.27bn to bolster the haematological cancer pipeline. As per the deal, AstraZeneca will make an upfront payment of $100m on the closing of the transaction.

Immune Response 147

Immune Response Gene Therapy Gene Development 147

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. The Sartorius-Polyplus deal is expected to close in Q3 2023. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

Pharmaceutical Technology

APRIL 26, 2023

The new deal excludes oncology and other therapeutic areas outside the scope of genetic disease. MiNA will receive an upfront payment and future royalties should BioMarin exercise options from the deal. Financial details of the deal were not divulged. Topic sponsors are not involved in the creation of editorial content.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Pharmaceutical Technology

SEPTEMBER 22, 2022

Sesen Bio has signed a definitive merger agreement to combine its business with Carisma Therapeutics and create a clinical-stage biotechnology firm in an all-stock deal. . On closing of the deal, the merged company will be called Carisma Therapeutics, and its headquarters will be located in Philadelphia, Pennsylvania, US.

Clinical Trials 130

Clinical Trials Clinical Trials Gene Therapy Trials 130

Pharmaceutical Technology

JULY 12, 2022

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. Topic sponsors are not involved in the creation of editorial content. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

Pharmaceutical Technology

DECEMBER 8, 2022

Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., Free Whitepaper.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

SEPTEMBER 21, 2022

Rocket Pharmaceuticals has entered a definitive agreement for the acquisition of biotechnology firm Renovacor in an all-stock equity deal worth nearly $53m, or $2.60 Subject to necessary closing conditions and approvals, the deal is anticipated to conclude in the first quarter of next year. for each share.

Gene Therapy 147

Gene Therapy Gene Cardiology Genetics 147

Pharmaceutical Technology

AUGUST 26, 2022

Under the 30-year deal, ElevateBio will set up its next BaseCamp process development and Good Manufacturing Practice (GMP) manufacturing facility in Pittsburgh. Additionally, the County of Allegheny and the Commonwealth of Pennsylvania contributed incentive grants to ElevateBio for supporting the deal of setting up a biomanufacturing centre.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Pharmaceutical Technology

AUGUST 1, 2022

Under this deal, SII will gain access to the technology platform of GreenLight for developing, producing and marketing up to three messenger RNA products in markets with a combined population of over five billion. Topic sponsors are not involved in the creation of editorial content.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

OCTOBER 25, 2022

According to the deal, Astellas will acquire 15% of Taysha’s outstanding common stock by making an investment totalling $50m. Topic sponsors are not involved in the creation of editorial content. This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Topic sponsors are not involved in the creation of editorial content.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

MARCH 28, 2023

Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. Topic sponsors are not involved in the creation of editorial content.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Pharmaceutical Technology

MARCH 30, 2023

The topical and oral form of the compound is intended to treat glaucoma and dry age-related macular degeneration (AMD), as well as other ophthalmic indications with high unmet medical need, in Africa, the Middle East, the Americas and Europe. It is currently ready to enter Phase II/III clinical trials.

Clinical Trials 130

Clinical Trials Clinical Trials Licensing Licensing 130

Pharmaceutical Technology

FEBRUARY 16, 2023

The preclinical research deal will combine the MicroOrganoSphere (MOS) platform of Xilis with the expertise of MD Anderson for advancing new therapies development and cancer research. Under the deal, MD Anderson and Xilis aim to advance the development of drug and discovery projects using the MOS technology.

Development 242

Development Gene Therapy Gene Drugs 242

Pharmaceutical Technology

JUNE 9, 2023

Astellas Pharma (Astellas) has entered an exclusive licence deal with Kate Therapeutics (KateTx) to develop and commercialise KT430. KateTx will use the proceeds from the financing and licence deal to advance its portfolio of muscle and heart disease programmes, including facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

Gene Therapy 147

Gene Therapy Gene Development Medicine 147

Pharmaceutical Technology

AUGUST 1, 2022

The US Department of Health and Human Services, and Administration for Strategic Preparedness and Response (ASPR) and others are supporting the deal through federal funds. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

Outsourcing Pharma

JULY 29, 2021

A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.

Regulation 52

Regulation Marketing 52

Pharmaceutical Technology

DECEMBER 12, 2022

As per the deal, Arcellx is entitled to $225m in upfront payment in cash following closing, as well as an equity investment of $100m from Kite. The deal is anticipated to conclude in the first quarter of next year. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Development 264

Development Gene Therapy Clinical Trials Clinical Trials 264

Pharmaceutical Technology

OCTOBER 26, 2022

According to the deal, CEPI will make a payment of up to $140m for R&D expenses to the company. Topic sponsors are not involved in the creation of editorial content. The post SK bioscience and CEPI enter mRNA vaccine development deal appeared first on Pharmaceutical Technology.

Vaccination 130

Vaccination Vaccine Development Gene Therapy 130

Pharmaceutical Technology

OCTOBER 18, 2022

According to the deal, the parties will cancel pending orders under the existing Covid-19 vaccine supply agreement for this year. Topic sponsors are not involved in the creation of editorial content. The post Moderna and Gavi announce update on Covid-19 vaccine supply deal appeared first on Pharmaceutical Technology.

Vaccination 130

Vaccination Vaccine Gene Therapy Containment 130

Pharmaceutical Technology

FEBRUARY 17, 2023

The latest move follows an exclusive distribution deal signed by the companies for CAP-1002 in the US in January last year. Under the new partnership deal, Nippon Shinyaku will have exclusive rights to commercialise and distribute the Capricor’s lead asset in Japan once approved.

Gene Therapy 130

Gene Therapy Sales Clinical Development Gene 130

Pharmaceutical Technology

APRIL 17, 2023

Both firms will explore private investment in public equity (PIPE) funding before concluding the deal, with NKGen’s majority stockholder NKMax backstopping up to $25m cash funded at $10.00 Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 246

Gene Therapy Gene Clinical Development Development 246

Pharmaceutical Technology

MARCH 29, 2023

Under the deal’s terms, Regeneron will make $75m in upfront payments to Sonoma Biotherapeutics, including a $30m equity investment. Topic sponsors are not involved in the creation of editorial content. Sonoma will also be eligible to receive a development milestone payment of $45m.

Development 245

Development Gene Therapy Gene Production 245

Pharmaceutical Technology

APRIL 27, 2023

Described as the largest reform in over 20 years, the proposed revision touches on multiple topics ranging from unequal access to innovative medicines across the EU to new environmental protections. The reform supports initiatives as part of the European Green Deal, specifically focusing on air, soil, and water pollution action plans.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Pharmaceutical Technology

JUNE 29, 2022

In a bid to meet the growing demand for automated and closed smart systems across the cell and gene therapy (CGT) industry, the companies entered the deal to merge technologies and capabilities. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 264

Gene Therapy Gene Manufacturing Production 264

Pharmaceutical Technology

DECEMBER 21, 2022

Topic sponsors are not involved in the creation of editorial content. The post Moderna and UK government sign deal to establish mRNA facility appeared first on Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Free Whitepaper.

Gene Therapy 351

Gene Therapy Vaccination Vaccine Manufacturing 351

Pharmaceutical Technology

OCTOBER 13, 2022

Under the collaboration deal, Inceptor Bio will use the Solupore technology from Avectas instead of electroporation for engineering T cells to yield a healthier T cell. Topic sponsors are not involved in the creation of editorial content. This non-viral technology is well suited to the CAR-T cell process of Inceptor Bio.

Development 147

Development Engineer Gene Therapy Gene 147

XTalks

FEBRUARY 8, 2022

The FDA’s Center for Food Safety and Applied Nutrition (CFSAN) and Office of Food Policy and Response (OFPR) recently released a list of draft and final guidance topics that are a priority for the agency’s Foods Program to complete in 2022. The FDA anticipates it will publish many of these documents by the beginning of next year.

Cosmetics 97

Cosmetics Regulation Genome Genomics 97

Pharmaceutical Technology

JUNE 16, 2023

It comes after Flamingo announced a deal in March 2023 to merge its operations with Dynacure. Topic sponsors are not involved in the creation of editorial content. It will also support the firm’s preclinical effort on the long non-coding RNA (LncRNA) programme, FTX-001, that targets MALAT-1.

RNA 173

RNA Gene Therapy Gene Clinical Trials 173

Pharmaceutical Technology

DECEMBER 23, 2022

As per this deal, Lilly will obtain access to further targets in the central nervous system and peripheral nervous system using the Axiomer platform. Topic sponsors are not involved in the creation of editorial content. Lilly will make an upfront payment and equity investment totalling $75m to ProQR. Free Whitepaper.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Drug Discovery World

MAY 8, 2023

Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021. Dr Andrew Woodland, CEO of Tay Therapeutics, said: “The second deal with VYNE is the culmination of two years of discovery and development of BET inhibitors with differentiated selectivity and safety profiles.

Licensing 52

Licensing Licensing Sales Development 52

Scienmag

DECEMBER 29, 2020

Scientific articles in the field of physics are mostly very short and deal with a very restricted topic. Researchers publish review article on the physics of interacting particles Credit: M. te Vrugt et al. A remarkable exception to this is an article published recently by physicists from the Universities of Münster and Düsseldorf.

Research 52

Research 52

Pharmaceutical Technology

DECEMBER 1, 2022

As per the deal, the combined company will focus on developing three cancer therapies, which originated from Thomas Jefferson University (TJU) in the US and South Korea-based Innobation Bio. Additionally, Liminatus intends to utilise the increased capital from this deal to advance its GCC CAR-T therapy to a clinical trial in humans.

Gene Therapy 130

Gene Therapy Clinical Trials Clinical Trials Immune Response 130

Pharmaceutical Technology

SEPTEMBER 29, 2022

According to the deal, Sanofi will make an upfront payment of $25m to Scribe. Topic sponsors are not involved in the creation of editorial content. The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer.

Development 130

Development In-Vivo Genome Genomics 130

pharmaphorum

NOVEMBER 2, 2021

Swiss group Novartis has swooped in with a backloaded option deal that includes $24 million upfront in cash and equity – plus up to $1.3 The approach has become a hot topic in biopharma with a string of big ticket partnerships over the last couple of years, including a $2.4 Others include a $1.6

Protein 98

Protein Licensing Licensing Drugs 98